The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …

Importance Liquid biopsy is an emerging tool with the potential to change oncologic care
practices. Optimal clinical applications for its use are currently undefined for surgical …

Human papillomavirus (HPV)-associated cancers, including oropharyngeal squamous cell
carcinoma (HPV+ OPSCC), cervical cancer, and squamous cell carcinoma of the anus …

In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through
accurate assessment of minimal residual disease (MRD) and therapeutic response …

Background Increasingly, circulating tumor DNA (ctDNA) is proposed as a tool for minimal
residual disease (MRD) assessment. Digital PCR (dPCR) offers low analysis costs and …

Background No reliable marker has been identified to predict postoperative recurrence of
gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 …

Purpose This was a review of circulating tumor DNA (ctDNA) in patients with peritoneal
metastases from colorectal cancer. Methods We searched the PubMed database for studies …

Circulating tumor DNA (ctDNA) is a promising biomarker, reflecting the presence of tumor
cells. Sequencing-based detection of ctDNA at low tumor fractions is challenging due to the …

Background There is accumulating evidence supporting the clinical use of circulating tumor
DNA (ctDNA) in solid tumors, especially in different types of gastrointestinal cancer. As such …